Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.45, for a total value of $680,550.00. Following the sale, the chief executive officer directly owned 711,164 shares of the company’s stock, valued at approximately $12,409,811.80. This trade represents a 5.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xingjuan Chao also recently made the following trade(s):

• On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $41,242.36.
• On Monday, January 5th, Xingjuan Chao sold 79,000 shares of CeriBell stock. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00.

CeriBell Trading Down 0.3%

NASDAQ CBLL opened at $17.83 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. The stock has a market capitalization of $671.12 million, a P/E ratio of -12.13 and a beta of 1.12. The firm’s 50-day moving average is $20.77 and its two-hundred day moving average is $16.46. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $24.33.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The business had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. On average, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Finally, TD Cowen reiterated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average target price of $24.67.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Quarterly results beat expectations: CeriBell reported a narrower-than-expected loss (EPS -$0.36 vs. -$0.43 est.) and revenue topped estimates, which is a constructive fundamental data point for future guidance and valuation. MarketBeat CBLL
• Positive Sentiment: Analyst backing remains favorable: multiple firms (Canaccord, TD Cowen, BTIG) maintain Buy/Overweight stances and some have raised targets (Canaccord to $30), supporting medium-term upside relative to current levels. MarketBeat Analyst Coverage
• Neutral Sentiment: Short-interest report shows an apparent increase but the published data contains anomalies (0 shares / NaN increase and 0.0 days-to-cover), so there’s no reliable signal of a true rise in short activity at this time.
• Negative Sentiment: CEO sale: CEO Xingjuan Chao sold 39,000 shares (~$680,550 at ~$17.45), reducing his stake by ~5.2% — a large insider disposition that can be perceived negatively by the market. SEC Filing – CEO Sale
• Negative Sentiment: Other senior insider sales: CTO Raymond Woo (8,087 shares, ~$147.6k), VP David Foehr (4,560 shares, ~$81.2k) and Director Rebecca Robertson (827 shares, ~$14.7k) all sold shares in early March; multiple concurrent sales by senior execs amplify negative perception. SEC Filing – CTO Sale SEC Filing – VP Sale InsiderTrades – Director Sale

Institutional Trading of CeriBell

Several hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd lifted its stake in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the last quarter. CWM LLC raised its holdings in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the last quarter. Finally, Larson Financial Group LLC grew its stake in shares of CeriBell by 1,403.1% during the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after purchasing an additional 2,680 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.